Original Publication Date: 1 April, 2015
Publication / Source: Biomarkers in Medicine
Authors: Francesco Caiazza, Louise Elliott, David Fennelly et al
Patients with metastatic colorectal cancer have a very poor prognosis. Incorporation of targeted molecular therapies, such as the anti-EGFR receptor monoclonal antibodies cetuximab and panitumumab, into treatment regimens has improved outcomes for patients with wild-type RAS tumors.